Eisai Co., Ltd.
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) today announce that they received the court decisions on October 6, 2006 (The US Eastern time) in response to ANDA-related summary judgment motions for Aciphex
(Active Ingredient Name: rabeprazole sodium, Product Name in Japan: Pariet
The Southern District Court of New York granted the summary judgment regarding the validity of Aciphex
's composition of matter patent in its ruling. The court reserved ruling on the enforceability arguments until after trial. We look forward to a trial and will vigorously defend the Aciphex
patent in order to protect our interests.
has been shown to have a rapid onset of action and a reliable inhibitory effect on acid secretion related to duodenal ulcers and gastro-esophageal reflux disease, which are confirmed in clinical studies. Aciphex
was launched in the U.S. in 1999 and is currently marketed in 79 countries worldwide.